STOCK TITAN

Autolus Therapeutics plc American Depositary Share - $AUTL STOCK NEWS

Welcome to our dedicated page for Autolus Therapeutics plc American Depositary Share news (Ticker: $AUTL), a resource for investors and traders seeking the latest updates and insights on Autolus Therapeutics plc American Depositary Share stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Autolus Therapeutics plc American Depositary Share's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Autolus Therapeutics plc American Depositary Share's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.16%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.34%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.42%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.78%
Tags
conferences
Autolus Therapeutics plc American Depositary Share

Nasdaq:AUTL

AUTL Rankings

AUTL Stock Data

1.11B
91.18M
18.04%
53.51%
1.57%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
LONDON

About AUTL

autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient’s own cells.